Viewing Study NCT03528694

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:00 AM
Ignite Modification Date: 2026-02-04 @ 12:16 PM
Study NCT ID: NCT03528694
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-25
First Post: 2018-02-28
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
Sponsor: AstraZeneca
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-muscle-invasive Bladder Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Durvalumab View
None BCG View
None MEDI4736 View
None NMIBC View
None PD-L1 View
None DFS View
None OS View